Nuravax Receives FDA Fast Track Designation for AV‑1959R, an Investigational Vaccine Designed to Help Prevent Alzheimer's Disease Before Symptoms...

San Francisco Chronicle · 2026-10-20 12:00 UTC

Nuravax, Inc., a clinical-stage biotechnology company developing vaccines for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track

Read the full story at San Francisco Chronicle · All coverage of this story